Ultragenyx Pharmaceutical Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Ultragenyx Pharmaceutical Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Ultragenyx Pharmaceutical Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$134M, a 16.4% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$559M, a 12% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$607M, a 14.2% increase from 2022.
  • Ultragenyx Pharmaceutical Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$707M, a 55.8% decline from 2021.
  • Ultragenyx Pharmaceutical Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$454M, a 143% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$559M -$134M +$26.1M +16.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$585M -$132M +$28.2M +17.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 -$613M -$171M -$6.71M -4.09% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-03
Q4 2023 -$607M -$123M +$28.6M +18.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 -$635M -$160M +$85.5M +34.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$721M -$160M -$1.67M -1.05% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 -$719M -$164M -$11.7M -7.65% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q4 2022 -$707M -$152M -$29.4M -24% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 -$678M -$245M -$172M -236% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$506M -$158M -$35.7M -29.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 -$470M -$152M -$16.2M -11.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 -$454M -$122M -$98.4M -410% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 -$356M -$73M -$4.15M -6.03% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$351M -$122M -$148M -584% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-29
Q1 2021 -$204M -$136M -$17.1M -14.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$187M -$24M +$69.8M +74.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-12
Q3 2020 -$256M -$68.8M +$44.1M +39.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$301M $25.3M +$124M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$425M -$119M -$22.3M -23% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$403M -$93.8M -$5.98M -6.81% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-12
Q3 2019 -$397M -$113M -$25.7M -29.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-12
Q2 2019 -$371M -$99.2M -$46.4M -88.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-12
Q1 2019 -$325M -$96.8M -$127M -420% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-12
Q4 2018 -$198M -$87.8M -$6.1M -7.46% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-14
Q3 2018 -$192M -$87.3M -$8.08M -10.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-14
Q2 2018 -$183M -$52.7M +$20.2M +27.7% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-14
Q1 2018 -$204M $30.3M +$98.5M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-14
Q4 2017 -$302M -$81.7M -$10.4M -14.7% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-20
Q3 2017 -$292M -$79.2M -$14.3M -22.1% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-20
Q2 2017 -$277M -$72.9M -$16M -28.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-20
Q1 2017 -$261M -$68.3M -$15.5M -29.4% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-20
Q4 2016 -$246M -$71.3M -$16.1M -29.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-21
Q3 2016 -$230M -$64.9M -$25.7M -65.4% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-21
Q2 2016 -$204M -$56.9M -$27.1M -91.1% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-21
Q1 2016 -$177M -$52.8M -$31.4M -147% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-21
Q4 2015 -$146M -$55.2M -$38.5M -230% Oct 1, 2015 Dec 31, 2015 10-K 2016-02-26
Q3 2015 -$107M -$39.2M -$23.4M -148% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 -$83.8M -$29.8M -$16.2M -119% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$67.6M -$21.4M -$7.75M -56.9% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$59.8M -$16.7M -$5.42M -47.9% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-26
Q3 2014 -$54.4M -$15.8M -$7.42M -88.1% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-26
Q2 2014 -$47M -$13.6M -$5M -58.1% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-26
Q1 2014 -$42M -$13.6M -$6.9M -102% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-26
Q4 2013 -$35.1M -$11.3M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-27
Q3 2013 -$8.43M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-27
Q2 2013 -$8.59M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-27
Q1 2013 -$6.74M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.